Search research articles

ACERCA DE JoVE

Visión General Liderazgo Blog Centro de Ayuda JoVE

AUTORES

Proceso de Publicación Consejo Editorial Alcance y Políticas Revisión por Pares Preguntas Frecuentes Enviar

BIBLIOTECARIOS

Testimonios Suscripciones Acceso Recursos Consejo Asesor de Bibliotecas Preguntas Frecuentes

INVESTIGACIÓN

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archivo

EDUCACIÓN

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Centro de Recursos para Profesores Sitio de Profesores

Términos y Condiciones de Uso

Política de Privacidad

Videos de Conceptos Relacionados

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Coronary Artery Disease IV: Preventive Measures

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por

Same author

Divergent risk profiles for cause-specific mortality in MASLD and MetALD: a nationwide population-based study.

Frontiers in medicine·2026

Same author

Efficacy and Long-Term Outcomes of Direct-Acting Antivirals in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

Gut and liver·2026

Same author

Solvent Engineering of Quasi-2D Dion-Jacobson Perovskites Reveals Narrow Composition Tolerance for Indoor Photovoltaics.

The journal of physical chemistry letters·2026

Same author

Timing and Associated Factors to Formation and Detection of Sequestrum in Patients With Medication-Related Osteonecrosis of the Jaw.

Oral diseases·2026

Same author

Machine learning-based prediction of hepatocellular carcinoma risk in steatotic liver disease: A nationwide cohort study.

PloS one·2026

Same author

Enhanced Enzyme Cascade Reactions Through Coencapsulation in Biocompatible Silica Nanoconfinement.

Chembiochem : a European journal of chemical biology·2026

Search research articles

Video Experimental Relacionado

Updated: Sep 9, 2025

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

La terapia antiviral reduce la dislipidemia y el riesgo cardiovascular en la hepatitis B crónica: el TDF es el agente

Hyuk Kim¹, Jae-Young Kim², Hyun Bin Choi¹

¹Department of Internal Medicine, Division of Gastroenterology and Hepatology, Soonchunhyang University Bucheon Hospital, Bucheon-si, Korea.

Journal of medical virology

|September 4, 2025

Resumen

La terapia antiviral para la hepatitis B crónica (CHB) reduce significativamente el riesgo de dislipidemia y de eventos cardiovasculares adversos mayores (MACE). El fumarato de tenofovir disoproxil (TDF) ofrece la protección más sustancial, destacando los beneficios extrahepáticos más allá de la supresión viral.

Palabras clave:

Agentes antivirales Dislipidemia seguro de salud acontecimientos adversos cardíacos importantes

Más Videos Relacionados

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

Videos de Experimentos Relacionados

Last Updated: Sep 9, 2025

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

Área de la Ciencia:

Hepatología
Cardiología
Síndrome metabólico

Sus antecedentes:

La hepatitis B crónica requiere tratamiento antiviral a largo plazo.
No se comprende completamente el impacto de la terapia antiviral con CHB en la salud metabólica y cardiovascular.

Objetivo del estudio:

Investigar los efectos de la terapia antiviral en la dislipidemia y los eventos adversos cardiovasculares mayores (EACM) en pacientes con EHC.
Evaluar los beneficios específicos del fumarato de tenofovir disoproxilo (TDF).

Principales métodos:

Estudio de cohorte retrospectivo a nivel nacional utilizando datos de la revisión y evaluación del seguro de salud coreano.
Coincidencia de la puntuación de propensión entre 48.606 pacientes tratados con CHB y controles no tratados.
Análisis de las tasas de incidencia y de los ratios de riesgo para la dislipidemia y la EMA.

Principales resultados:

La terapia antiviral redujo significativamente las tasas de incidencia de dislipidemia (IRR: 0,80) y de MACE (IRR: 0,78).
El fumarato de tenofovir disoproxil (TDF) demostró los efectos protectores más fuertes (aHR: 0,52 para la dislipidemia, 0,58 para el MACE).
Los efectos protectores fueron más pronunciados en pacientes no diabéticos.

Conclusiones:

La terapia antiviral para CHB ofrece beneficios extrahepáticos significativos, incluido el riesgo reducido de dislipidemia y MACE.
El TDF es particularmente eficaz para mitigar estos riesgos.
Estos hallazgos apoyan el uso de la terapia antiviral en el tratamiento integral a largo plazo de la EHC.